Hostname: page-component-76d6cb85b7-92wsb Total loading time: 0 Render date: 2026-07-14T12:07:54.673Z Has data issue: false hasContentIssue false
  • English
  • Français

Telomerase inhibition in malignant gliomas: a systematic review

Part of: Drug Discovery

Published online by Cambridge University Press:  15 March 2023

Quintino Giorgio D'Alessandris Open the ORCID record for Quintino Giorgio D'Alessandris [Opens in a new window] ,
Marco Battistelli ,
Giovanni Pennisi ,
Martina Offi ,
Maurizio Martini ,
Tonia Cenci ,
Maria Laura Falchetti ,
Liverana Lauretti ,
Alessandro Olivi  and
Roberto Pallini
...Show all authors
Quintino Giorgio D'Alessandris*
Affiliation:
Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
Marco Battistelli
Affiliation:
Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy Department of Neuroscience, Neurosurgery Section, Università Cattolica del Sacro Cuore, Rome, Italy
Giovanni Pennisi
Affiliation:
Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy Department of Neuroscience, Neurosurgery Section, Università Cattolica del Sacro Cuore, Rome, Italy
Martina Offi
Affiliation:
Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy Department of Neuroscience, Neurosurgery Section, Università Cattolica del Sacro Cuore, Rome, Italy
Maurizio Martini
Affiliation:
Department of Pathology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
Tonia Cenci
Affiliation:
Department of Pathology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
Maria Laura Falchetti
Affiliation:
CNR-Institute of Biochemistry and Cell Biology (IBBC), Monterotondo, Rome, Italy
Liverana Lauretti
Affiliation:
Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy Department of Neuroscience, Neurosurgery Section, Università Cattolica del Sacro Cuore, Rome, Italy
Alessandro Olivi
Affiliation:
Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy Department of Neuroscience, Neurosurgery Section, Università Cattolica del Sacro Cuore, Rome, Italy
Roberto Pallini
Affiliation:
Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy Department of Neuroscience, Neurosurgery Section, Università Cattolica del Sacro Cuore, Rome, Italy
Nicola Montano
Affiliation:
Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy Department of Neuroscience, Neurosurgery Section, Università Cattolica del Sacro Cuore, Rome, Italy
*
Author for correspondence: Quintino Giorgio D'Alessandris, E-mails: giorgiodal@hotmail.it; quintinogiorgio.dalessandris@policlinicogemelli.it
Get access Rights & Permissions [Opens in a new window]

Abstract

Glioblastoma (GBM) is the most frequent adult malignant brain tumour and despite different therapeutic efforts, the median overall survival still ranges from 14 to 18 months. Thus, new therapeutic strategies are urgently needed. However, the identification of cancer-specific targets is particularly challenging in GBM, due to the high heterogeneity of this tumour in terms of histopathological, molecular, genetic and epigenetic features. Telomerase reactivation is a hallmark of malignant glioma. An activating mutation of the hTERT gene, encoding for the active subunit of telomerase, is one of the molecular criteria to establish a diagnosis of GBM, IDH-wildtype, in the 2021 WHO classification of central nervous system tumours. Telomerase inhibition therefore represents, at least theoretically, a promising strategy for GBM therapy: pharmacological compounds, as well as direct gene expression modulation therapies, have been successfully employed in in vitro and in vivo settings. Unfortunately, the clinical applications of telomerase inhibition in GBM are currently scarce. The aim of the present systematic review is to provide an up-to-date report on the studies investigating telomerase inhibition as a therapeutic strategy for malignant glioma in order to foster the future translational and clinical research on this topic.

Keywords

Alternative lengthening of telomeresglioblastomahTERTin vitroin vivotelomerase

Information

Type
Review
Information
Expert Reviews in Molecular Medicine , Volume 25 , 2023 , e10
Check for updates
Copyright
Copyright © The Author(s), 2023. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Footnotes

*

These two authors shared the senior authorship.

References

Preusser, M et al. (2011) Current concepts and management of glioblastoma. Annals of Neurology 70, 9–21.CrossRefGoogle ScholarPubMed
D'alessandris, QG et al. (2023) Tailored therapy for recurrent glioblastoma. Report of a personalized molecular approach. Journal of Neurosurgical Sciences 67, 103–107.Google ScholarPubMed
Louis, DN et al. (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-Oncology 23, 1231–1251.CrossRefGoogle ScholarPubMed
Tchirkov, A et al. (2003) Clinical implications of quantitative real-time RT-PCR analysis of hTERT gene expression in human gliomas. British Journal of Cancer 88, 516–520.CrossRefGoogle ScholarPubMed
He, Y and Feigon, J (2022) Telomerase structural biology comes of age. Current Opinion in Structural Biology 76, 102446.CrossRefGoogle ScholarPubMed
Bollam, SR, Berens, ME and Dhruv, HD (2018) When the ends are really the beginnings: targeting telomerase for treatment of GBM. Current Neurology and Neuroscience Reports 18, 15.CrossRefGoogle ScholarPubMed
Arita, H et al. (2016) A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathologica Communications 4, 79.CrossRefGoogle ScholarPubMed
Pallini, R et al. (2006) Telomerase inhibition by stable RNA interference impairs tumor growth and angiogenesis in glioblastoma xenografts. International Journal of Cancer 118, 2158–2167.CrossRefGoogle ScholarPubMed
Moher, D et al. (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 6, e1000097.CrossRefGoogle ScholarPubMed
Mirzazadeh, A et al. (2017) Assessment effects of resveratrol on human telomerase reverse transcriptase messenger ribonucleic acid transcript in human glioblastoma. Advanced Biomedical Research 6, 73.CrossRefGoogle Scholar
Gurung, RL et al. (2010) Thymoquinone induces telomere shortening, DNA damage and apoptosis in human glioblastoma cells. PLoS ONE 5, 12124.CrossRefGoogle ScholarPubMed
Khaw, AK et al. (2007) Inhibition of telomerase activity and human telomerase reverse transcriptase gene expression by histone deacetylase inhibitor in human brain cancer cells. Mutation Research 625, 134–144.CrossRefGoogle ScholarPubMed
Khaw, AK et al. (2013) Curcumin inhibits telomerase and induces telomere shortening and apoptosis in brain tumour cells. Journal of Cellular Biochemistry 114, 1257–1270.CrossRefGoogle ScholarPubMed
Khaw, AK et al. (2015) Plumbagin alters telomere dynamics, induces DNA damage and cell death in human brain tumour cells. Mutation Research: Genetic Toxicology and Environmental Mutagenesis 793, 86–95.CrossRefGoogle ScholarPubMed
Khaw, AK et al. (2012) Genistein induces growth arrest and suppresses telomerase activity in brain tumor cells. Genes Chromosomes Cancer 51, 961–974.CrossRefGoogle Scholar
Lin, P-C et al. (2011) Butylidenephthalide suppresses human telomerase reverse transcriptase (TERT) in human glioblastomas. Annals of Surgical Oncology 18, 3514–3527.CrossRefGoogle ScholarPubMed
Kiaris, H and Schally, AV (1999) Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone. Proceedings of the National Academy of Sciences of the USA 96, 226–231.CrossRefGoogle ScholarPubMed
Udroiu, I, Marinaccio, J and Sgura, A (2019) Epigallocatechin-3-gallate induces telomere shortening and clastogenic damage in glioblastoma cells. Environmental and Molecular Mutagenesis 60, 683–692.CrossRefGoogle ScholarPubMed
Das, A, Banik, NL and Ray, SK (2007) Differentiation decreased telomerase activity in rat glioblastoma C6 cells and increased sensitivity to IFN-gamma and taxol for apoptosis. Neurochemical Research 32, 2167–2183.CrossRefGoogle ScholarPubMed
Lavanya, C et al. (2018) Down regulation of human telomerase reverse transcriptase (hTERT) expression by BIBR1532 in human glioblastoma LN18 cells. Cytotechnology 70, 1143–1154.CrossRefGoogle ScholarPubMed
Biray Avci, C et al. (2018) Effects of telomerase inhibitor on epigenetic chromatin modification enzymes in malignancies. Journal of Cellular Biochemistry 119, 9817–9824.CrossRefGoogle ScholarPubMed
Li, Q et al. (2020) Antitumor activity and mechanism of costunolide and dehydrocostus lactone: two natural sesquiterpene lactones from the Asteraceae family. Biomedicine & Pharmacotherapy 125, 109955.CrossRefGoogle ScholarPubMed
Ahmad, F et al. (2016) Nrf2-driven TERT regulates pentose phosphate pathway in glioblastoma. Cell Death & Disease 7, e2213–e2213.CrossRefGoogle ScholarPubMed
Gurung, RL et al. (2014) Targeting DNA-PKcs and telomerase in brain tumour cells. Molecular Cancer 13, 232.CrossRefGoogle ScholarPubMed
Takahashi M et al. (2019) Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts. Cancer Science 110, 2247–2257.CrossRefGoogle Scholar
Marian, CO et al. (2010) The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clinical Cancer Research 16, 154–163.CrossRefGoogle ScholarPubMed
Ferrandon, S et al. (2015) Telomerase inhibition improves tumor response to radiotherapy in a murine orthotopic model of human glioblastoma. Molecular Cancer 14, 134.CrossRefGoogle Scholar
Ozawa, T et al. (2004) Antitumor effects of specific telomerase inhibitor GRN163 in humanglioblastoma xenografts. Neuro-Oncology 6, 218–226.CrossRefGoogle ScholarPubMed
Bejarano, L et al. (2017) Inhibition of TRF1 telomere protein impairs tumor initiation and progression in glioblastoma mouse models and patient-derived xenografts. Cancer Cell 32, 590–607.e4.CrossRefGoogle ScholarPubMed
Zhou, G et al. (2016) Telomere targeting with a novel G-quadruplex-interactive ligand BRACO-19 induces T-loop disassembly and telomerase displacement in human glioblastoma cells. Oncotarget 7, 14925–14939.CrossRefGoogle ScholarPubMed
Lagah, S et al. (2014) RHPS4 G-quadruplex ligand induces anti-proliferative effects in brain tumor cells. PLoS ONE 9, e86187.CrossRefGoogle ScholarPubMed
Mancini, A et al. (2018) Disruption of the β1L isoform of GABP reverses glioblastoma replicative immortality in a TERT promoter mutation-dependent manner. Cancer Cell 34, 513–528.e8.CrossRefGoogle Scholar
George, J, Banik, NL and Ray, SK (2009) Combination of hTERT knockdown and IFN-gamma treatment inhibited angiogenesis and tumor progression in glioblastoma. Clinical Cancer Research 15, 7186–7195.CrossRefGoogle ScholarPubMed
Falchetti, ML et al. (2006) Telomerase inhibition impairs tumor growth in glioblastoma xenografts. Neurological Research 28, 532–537.CrossRefGoogle ScholarPubMed
Falchetti, ML et al. (2008) Inhibition of telomerase in the endothelial cells disrupts tumor angiogenesis in glioblastoma xenografts. International Journal of Cancer, 122, 1236–1242.CrossRefGoogle ScholarPubMed
Lavanya, C et al. (2016) RNA interference mediated downregulation of human telomerase reverse transcriptase (hTERT) in LN18 cells. Cytotechnology 68, 2311–2321.CrossRefGoogle ScholarPubMed
Wang, Y-Y et al. (2012) MiR-21 modulates hTERT through a STAT3-dependent manner on glioblastoma cell growth. CNS Neuroscience & Therapeutics 18, 722–728.CrossRefGoogle ScholarPubMed
Flores, I, Benetti, R and Blasco, MA (2006) Telomerase regulation and stem cell behaviour. Current Opinion in Cell Biology 18, 254–260.CrossRefGoogle ScholarPubMed
Kim, S et al. (2020) Inhibition of MUC1 exerts cell-cycle arrest and telomerase suppression in glioblastoma cells. Scientific Reports 10, 18238.CrossRefGoogle ScholarPubMed
Vinchure, OS et al. (2021) miR-490 suppresses telomere maintenance program and associated hallmarks in glioblastoma. Cellular and Molecular Life Sciences: CMLS 78, 2299–2314.CrossRefGoogle ScholarPubMed
Mascarenhas, J et al. (2022) Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design. Future Oncology 18, 2393–2402.CrossRefGoogle ScholarPubMed